$GOSS
Gossamer Bio, Inc. Stock $goss

$goss Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000172811721000056 Filed on May 06, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.35M	$10.75M
YoY Change	5.58%	33.87%
% of Gross Profit
Research & Development	$41.83M	$41.41M
YoY Change	1.0%	65.77%
% of Gross Profit
Depreciation & Amortization	$400.0K	$329.0K
YoY Change	21.58%	94.67%
% of Gross Profit
Operating Expenses	$53.20M	$54.97M
YoY Change	-3.21%	61.59%
Operating Profit	-$53.20M	-$54.97M
YoY Change	-3.21%	61.59%
Interest Expense	$4.780M	$707.0K
YoY Change	576.1%	3621.05%
% of Operating Profit
Other Income/Expense, Net	-$4.438M	$893.0K
YoY Change	-596.98%	-36.49%
Pretax Income	-$57.64M	-$54.07M
YoY Change	6.6%	65.81%
Income Tax
% Of Pretax Income
Net Earnings	-$57.64M	-$54.07M
YoY Change	6.6%	65.82%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.78	-$0.87
Diluted Earnings Per Share	-$0.78	-$0.87
COMMON SHARES
Basic Shares Outstanding	74.09M shares	61.89M shares
Diluted Shares Outstanding	74.09M shares	61.89M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$453.3M	$346.2M
YoY Change	30.94%	-28.05%
Cash & Equivalents	$439.7M	$111.4M
Short-Term Investments	$13.60M	$234.8M
Other Short-Term Assets	$12.60M	$9.300M
YoY Change	35.48%	-43.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$465.8M	$355.4M
YoY Change	31.08%	-28.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.920M	$15.40M
YoY Change	-61.56%	274.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.010M	$600.0K
YoY Change	68.33%	-71.82%
Total Long-Term Assets	$16.62M	$16.10M
YoY Change	3.24%	-11.35%
TOTAL ASSETS
Total Short-Term Assets	$465.8M	$355.4M
Total Long-Term Assets	$16.62M	$16.10M
Total Assets	$482.5M	$371.5M
YoY Change	29.87%	-28.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.073M	$2.600M
YoY Change	-58.73%	-42.83%
Accrued Expenses	$16.86M	$25.80M
YoY Change	-34.64%	227.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$29.44M	$28.40M
YoY Change	3.68%	12.91%
LONG-TERM LIABILITIES
Long-Term Debt	$28.82M	$28.50M
YoY Change	1.13%
Other Long-Term Liabilities	$7.000M	$8.100M
YoY Change	-13.58%	-22.86%
Total Long-Term Liabilities	$28.82M	$36.60M
YoY Change	-21.25%	248.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.44M	$28.40M
Total Long-Term Liabilities	$28.82M	$36.60M
Total Liabilities	$210.4M	$65.00M
YoY Change	223.67%	82.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$635.2M	-$388.2M
YoY Change	63.61%	108.2%
Common Stock	$907.1M	$695.2M
YoY Change	30.48%	4.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$272.1M	$306.5M
YoY Change
Total Liabilities & Shareholders Equity	$482.5M	$371.5M
YoY Change	29.88%	-28.0%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$57.64M	-$54.07M
YoY Change	6.6%	65.82%
Depreciation, Depletion And Amortization	$400.0K	$329.0K
YoY Change	21.58%	94.67%
Cash From Operating Activities	-$58.90M	-$52.30M
YoY Change	12.62%	88.29%
INVESTING ACTIVITIES
Capital Expenditures	$802.0K	$513.0K
YoY Change	56.34%	47.84%
Acquisitions
YoY Change
Other Investing Activities	$12.77M	$28.55M
YoY Change	-55.27%	-114.43%
Cash From Investing Activities	$11.97M	$28.04M
YoY Change	-57.32%	-114.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$774.0K	$571.0K
YoY Change	35.55%	-99.8%
NET CHANGE
Cash From Operating Activities	-$58.90M	-$52.30M
Cash From Investing Activities	$11.97M	$28.04M
Cash From Financing Activities	$774.0K	$571.0K
Net Change In Cash	-$46.40M	-$23.69M
YoY Change	95.88%	-136.2%
FREE CASH FLOW
Cash From Operating Activities	-$58.90M	-$52.30M
Capital Expenditures	$802.0K	$513.0K
Free Cash Flow	-$59.70M	-$52.81M
YoY Change	13.05%	87.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001728117
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-38796
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	GOSSAMER BIO, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-5461709
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3013 Science Park Road
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021Q1	dei	City Area Code CityAreaCode	858
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	684-1300
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021Q1	dei	Trading Symbol TradingSymbol	GOSS
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	75909708	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	439659000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	486055000	USD
CY2021Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	13638000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	26573000	USD
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	565000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	565000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11985000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9129000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	465847000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	522322000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5920000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5534000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9692000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10550000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1010000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1027000	USD
CY2021Q1	us-gaap	Assets Assets	482469000	USD
CY2020Q4	us-gaap	Assets Assets	539433000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1073000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7508000	USD
CY2021Q1	goss	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	11509000	USD
CY2020Q4	goss	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	10431000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16862000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20711000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	29444000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38650000	USD
CY2021Q1	goss	Long Term Convertible Senior Notes LongTermConvertibleSeniorNotes	145168000	USD
CY2020Q4	goss	Long Term Convertible Senior Notes LongTermConvertibleSeniorNotes	143642000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28823000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28744000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6950000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7713000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	210385000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	218749000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	70000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	70000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75903538	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74493150	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75524254	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73874904	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	907089000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	897607000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-635171000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577530000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	158000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	599000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	272084000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	320684000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	482469000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	539433000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	41827000	USD
CY2020Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	41414000	USD
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	30000	USD
CY2020Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2805000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11346000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10748000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	53203000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	54967000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-53203000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-54967000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	193000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1598000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	4780000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	707000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	149000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4438000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	893000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-57641000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-54074000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-372000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-87000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-69000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-676000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-441000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-763000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58082000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54837000	USD
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8244000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74093526	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74093526	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61890323	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61890323	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	320684000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8708000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	759000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-57641000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-441000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	272084000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	352485000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	556000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-54074000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-763000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	306463000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-57641000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-54074000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	416000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	329000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8708000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8244000	USD
CY2021Q1	goss	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	30000	USD
CY2020Q1	goss	In Process Research And Development Expenses InProcessResearchAndDevelopmentExpenses	2805000	USD
CY2021Q1	goss	Amortization Of Operating Lease Right Of Use Assets AmortizationOfOperatingLeaseRightOfUseAssets	858000	USD
CY2020Q1	goss	Amortization Of Operating Lease Right Of Use Assets AmortizationOfOperatingLeaseRightOfUseAssets	566000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1605000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	89000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-66000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	65000	USD
CY2021Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2020Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	39000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2855000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1785000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-16000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-925000	USD
CY2021Q1	goss	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-117000	USD
CY2020Q1	goss	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	566000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6565000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1609000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1771000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2239000	USD
CY2021Q1	goss	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	1078000	USD
CY2020Q1	goss	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-2461000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-6500000	USD
CY2020Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-5633000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-58896000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52295000	USD
CY2021Q1	goss	Payments For Proceeds From Research And Development Asset Acquisitions PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions	30000	USD
CY2020Q1	goss	Payments For Proceeds From Research And Development Asset Acquisitions PaymentsForProceedsFromResearchAndDevelopmentAssetAcquisitions	2805000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	73778000	USD
CY2021Q1	goss	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	12800000	USD
CY2020Q1	goss	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	89083000	USD
CY2021Q1	goss	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0	USD
CY2020Q1	goss	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	16051000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	802000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	513000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11968000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28038000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	774000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	571000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-242000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-50000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46154000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23686000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	486620000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135089000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	440224000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111353000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	675000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	618000	USD
CY2021Q1	goss	Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax	-69000	USD
CY2020Q1	goss	Noncash Investing And Financing Activities Change In Unrealized Gain On Marketable Securities Net Of Tax NoncashInvestingAndFinancingActivitiesChangeInUnrealizedGainOnMarketableSecuritiesNetOfTax	-676000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	60000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-635200000	USD
	goss	Funds Raised Through Preferred Equity Financing Convertible Note Financings And Completed Initial Public Offering FundsRaisedThroughPreferredEquityFinancingConvertibleNoteFinancingsAndCompletedInitialPublicOffering	942000000.0	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the allocation of the 2027 Notes into liability and equity components and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8959000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8157000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3039000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2623000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5920000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5534000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6453000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12194000	USD
CY2021Q1	us-gaap	Interest Payable Current InterestPayableCurrent	3594000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1094000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3518000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3633000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2349000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2823000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	733000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	742000	USD
CY2021Q1	goss	Accrued In Process Research And Development AccruedInProcessResearchAndDevelopment	215000	USD
CY2020Q4	goss	Accrued In Process Research And Development AccruedInProcessResearchAndDevelopment	225000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16862000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20711000	USD
CY2021Q1	us-gaap	Fair Value Equity Level2 To Level1 Transfers Amount FairValueEquityLevel2ToLevel1TransfersAmount	0	USD
CY2021Q1	us-gaap	Fair Value Equity Level1 To Level2 Transfers Amount FairValueEquityLevel1ToLevel2TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Equity Level1 To Level2 Transfers Amount FairValueEquityLevel1ToLevel2TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Equity Level2 To Level1 Transfers Amount FairValueEquityLevel2ToLevel1TransfersAmount	0	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	13530000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	108000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	13638000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue	13638000	USD
CY2021Q1	goss	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	13638000	USD
CY2020Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	1649348	shares
CY2021Q1	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	1410385	shares
CY2018Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	20000000.0	USD
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	30000	USD
CY2020Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2805000	USD
CY2021Q1	goss	Common Stock Voting Rights Number Of Votes Per Share CommonStockVotingRightsNumberOfVotesPerShare	1	vote
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9433963	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.25
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117100000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9464000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9401082	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.42
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10182000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2215526	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.82
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5721	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.61
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	220656	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	16.06
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11390231	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.83
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4431654	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	12.76
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y3M18D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	6558000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	8.08
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8708000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8244000	USD
CY2019Q4	goss	Option To Extend Contract Exercise Period OptionToExtendContractExercisePeriod	P9M
CY2020Q1	us-gaap	Sublease Income SubleaseIncome	0	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M12D
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1038000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	753000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	9000	USD
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	22000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	1047000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	775000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1100000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	800000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3213000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3579000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2063000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2123000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	387000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	397000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11762000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1294000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10468000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3518000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6950000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10468000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1000000.0	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000	USD

Files In Submission

Name	View Source	Status
0001728117-21-000056-index-headers.html	Edgar Link	pending
0001728117-21-000056-index.html	Edgar Link	pending
0001728117-21-000056.txt	Edgar Link	pending
0001728117-21-000056-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
goss-20210331.htm	Edgar Link	pending
goss-20210331.xsd	Edgar Link	pending
goss-20210331x10qxexx101.htm	Edgar Link	pending
goss-20210331x10qxexx311.htm	Edgar Link	pending
goss-20210331x10qxexx312.htm	Edgar Link	pending
goss-20210331x10qxexx321.htm	Edgar Link	pending
goss-20210331x10qxexx322.htm	Edgar Link	pending
goss-20210331_cal.xml	Edgar Link	unprocessable
goss-20210331_def.xml	Edgar Link	unprocessable
goss-20210331_htm.xml	Edgar Link	completed
goss-20210331_lab.xml	Edgar Link	unprocessable
goss-20210331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GOSS
Gossamer Bio, Inc. Stock $goss

2021 Q1 Form 10-Q Financial Statement

#000172811721000056 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOSS Gossamer Bio, Inc. Stock $goss

2021 Q1 Form 10-Q Financial Statement

#000172811721000056 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOSS
Gossamer Bio, Inc. Stock $goss